Genoway

Genoway Net Change in Cash

The Net Change in Cash of Genoway (ALGEN.PA) as of Oct 21, 2026 is 2.10 M EUR. In the previous year, Net Change in Cash was 698,069.00 EUR — a change of 200.32% (higher).

Net Change in Cash

2.10 MEUR

YoY

200.32%

Last updated:

Net Change in Cash of Genoway is 2025 2.10 M EUR. Net Change in Cash of Genoway was 2024 698,069.00 EUR. It decreases by 200.32% higher compared to the previous year.

The Genoway Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
-894,714.00 EUR
Jan 1, 2019
-1.96 M EUR
Jan 1, 2020
1.63 M EUR
Jan 1, 2021
2.88 M EUR
Jan 1, 2022
-727,349.00 EUR
Jan 1, 2023
-621,785.00 EUR
Jan 1, 2024
698,069.00 EUR
Jan 1, 2025
2.10 M EUR
The Genoway Net Change in Cash history
YEARNet Change in CashYoY
2.10 MEUR+200.32%
698,069.00EUR-212.27%
-621,785.00EUR-14.51%
-727,349.00EUR-125.21%
2.88 MEUR+76.52%
1.63 MEUR-183.19%
-1.96 MEUR+119.57%
-894,714.00EUR-168.19%
1.31 MEUR-214.73%
-1.14 MEUR-784.61%
167,045.00EUR-117.90%
-933,049.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genoway Stock analysis

What does Genoway do? Genoway SA is a biotechnology company based in Lyon, France. It was founded in 2002 by Pierre Cadinot. The company specializes in the production of genetically modified mice for disease research and the development of new therapies. The business model of Genoway is to provide customers with customized genetically modified mice. The company offers a wide range of services, from consulting during the design phase to the delivery of modified mice. The company also offers services in the field of cell culture and transgene expression. Genoway is divided into different divisions to meet specific customer needs. For example, there is the "Knockout Mice" division, which specializes in producing mice that lack a specific target gene. These mice are used to study the function of the missing gene in vivo. Another area of Genoway is the production of "humanized mouse models". These are mice in which human genes have been inserted to model specific human diseases or to test the efficacy of drugs. These humanized mice are an important part of drug research in the pharmaceutical industry. Genoway also offers services in the field of inducible expression. This involves triggering the expression of a target gene in vivo to study the effects of the protein. This technology is particularly useful in the research of diseases such as cancer, where certain genes are only active in specific cells. In addition to these specialized services, Genoway also offers a wide range of standard services, such as the creation of stable cell lines or transgene expression in various organs and tissues. Genoway is a leading company in the development of genetically modified models for the study of human diseases. The company works closely with its customers to develop customized solutions that meet the specific requirements of each project. With its divisions and services, it aims to support its customers in the development of new therapies and drugs. Genoway is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genoway stock

Net Change in Cash of Genoway is 2.10 M EUR in 2025.

Net Change in Cash of Genoway changed from 698,069.00 EUR to 2.10 M EUR, representing a 200.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Genoway since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Genoway historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genoway

All Key Metrics — Genoway